

EBITDA margin expansion was a key positive

- Marico's Q1FY21 revenues came in line, but EBITDA and APAT exceed our estimates. India business posted 15% revenue decline with 14% volume de-growth.
- Barring VAHO (-4.9%), Parachute (+1.9%) and Saffola (+9.5%) reported positive volume CAGR over last 3 years, was encouraging.
- Saffola continues to outperform with 16% value/volume growth. Consumer up-stocking helped the brand to post better growth during the quarter.
- A +140bps YoY improvement in GM and 300bps decline in A&P spends helped operating margins to expand. Going ahead, we expect mild inflation in copra prices but A&P spends are likely to remain low.
- We also believe that Parachute volumes would recover faster, as the secondary sales continue to remain positive.
- We maintain our FY21E and FY22E EPS estimates at Rs 8.5 and Rs 9.1 respectively. Valuing the stock at 40x FY22E EPS to arrive at a TP of Rs 364. Maintain Accumulate (Buy on Dips).

Operational performance was ahead of our estimate

Revenues declined 11.1% YoY to Rs 19.3bn. Domestic business reported 15% revenue de-growth whereas IB posted 2% growth. Marico reported 14% volume de-growth in Domestic Business. EBITDA increased by 1.3% YoY to Rs 4.7bn - came ahead of our estimate. EBITDA margin expanded by 300bps to 24.3% as 110/20bps increase in employee cost/other expenses was completely offset by 300/140bps decline in A&P spends/RM costs respectively. APAT declined by 3.0% to Rs 3.2bn- came ahead of our estimate.

Parachute performance was satisfactory

Parachute de-grew by 12% in value with 11% volume de-growth. The performance was encouraging considering (1) lockdown in the beginning of the quarter (2) Non-essential nature of the category and (3) unfavourable volume base of the brand (+9%). Consequently, we believe that Parachute growth would normalize faster compared to other hair oil brands once market conditions normalize. However, as there is less room for further decline in copra price, GM expansion would remain a challenge.

Q1FY21 Result (Rs Mn)

Particulars	Q1FY21	Q1FY20	YoY (%)	Q4FY20	QoQ (%)
Revenue	19,250	21,660	(11.1)	14,960	28.7
Total Expense	14,580	17,050	(14.5)	12,140	20.1
EBITDA	4,670	4,610	1.3	2,820	65.6
Depreciation	340	350	(2.9)	380	(10.5)
EBIT	4,330	4,260	1.6	2,440	77.5
Other Income	190	280	(32.1)	320	(40.6)
Interest	90	120	(25.0)	130	(30.8)
EBT	5,070	4,230	19.9	2,530	100.4
Тах	1,170	1,080	8.3	530	120.8
RPAT	3,880	3,150	23.2	1,990	95.0
APAT	3,240	3,340	(3.0)	2,090	55.0
			(bps)		(bps)
Gross Margin (%)	48.9	47.5	138	49.3	(38)
EBITDA Margin (%)	24.3	21.3	298	18.9	541
NPM (%)	20.2	14.5	561	13.3	685
Tax Rate (%)	23.1	25.5	(246)	20.9	213
EBIT Margin (%)	22.5	19.7	283	16.3	618

СМР	Rs 350
Target / Upside	Rs 364 / 4%
BSE Sensex	37,920
NSE Nifty	11,132
Scrip Details	
Equity / FV	Rs 1,291mn / Rs 1
Market Cap	Rs 452bn
	US\$ 6bn
52-week High/Low	Rs 404/Rs 234
Avg. Volume (no)	3,423,700
NSE Symbol	MARICO
Bloomberg Code	MRCO IN
Shareholding Patte	ern Jun'20(%)
Promoters	59.6
MF/Banks/FIs	9.7
FIIs	23.7
Public / Others	7.0

Valuation (x)

	FY20A	FY21E	FY22E
P/E	43.1	41.0	38.3
EV/EBITDA	30.4	30.4	28.9
ROE (%)	33.9	34.4	33.0
RoACE (%)	35.0	33.8	31.8

Estimates (Rs mn)

	FY20A	FY21E	FY22E
Revenue	73,150	73,596	79,419
EBITDA	14,690	14,646	15,304
PAT	10,501	11,028	11,809
EPS (Rs.)	8.1	8.5	9.1

VP Research: Sachin Bobade Tel: +91 22 40969731

E-mail: sachinb@dolatcapital.com

Associate: Nikhat Koor

Tel: +91 22 40969764 E-mail: nikhatk@dolatcapital.com





Other segments posted mixed performance

Other segments posted mixed performance during the quarter – (1) Value added hair oils (VAHO) declined by 32% in value, 30% in volume terms during the quarter, (2) Saffola posted 16% value and volume growth. The brand was benefited from upstocking by the consumers, (3) Premium hair nourishment and male grooming portfolio was impacted during the lock down period, however, better offtake during June, assures improvement in sales.

Gains in Bangladesh were offset due to pandemic

IB posted 4% decline as MENA, South Africa and South East Asia declined by 27%, 25% and 17% (in cc terms) respectively was partially restricted by 10% growth in Bangladesh (in cc terms). In Bangladesh, Parachute reported 6% growth and is expected to maintain single digit growth in the geography due to maturity of the brand. Non-coconut oil portfolio reported 18% growth in Bangladesh. Covid-19 outbreak hampered sales in other markets.

Exhibit 1: Actual V/s DART estimates

Rs mn	Actual	Estimates	Variance (%) Comments
Revenue	19,250	18,629	3.3
EBITDA	4,670	4,150	12.5
EBITDA margin %	24.3	22.3	200 EBITDA margin was higher than estimate due to lower A&SP and other expenses
APAT	3,240	2,902	11.6 Variation due to cascading effect of higher EBITDA

Source: Company, DART

Exhibit 2:	Change	in estimate
------------	--------	-------------

Rs Mn	FY21E			FY22E			
	New	Previous	Chg. (%)	New	Previous	Chg. (%)	
Net Revenue	73,596	73,596	0.0	79,419	79,419	0.0	
EBITDA	14,646	14,646	0.0	15,304	15,304	0.0	
EBITDA Margin (%)	19.9	19.9	0 bps	19.3	19.3	0 bps	
APAT	11,028	11,028	0.0	11,809	11,809	0.0	
Adj EPS (Rs)	8.5	8.5	0.0	9.1	9.1	0.0	

Source: DART, Company

We have maintained our revenue estimates for FY21E and FY22E as Q1FY21E revenues were in line with our forecast. Though OPM was marginally ahead of our estimate, we have maintained our estimate to factor in slight increase in RM and A&P spends going ahead. We also remain cautious about fresh lock downs in select states in July'20.





Exhibit 3: Key presence across product portfolio

Brands	Category	Indicative market share range %	Rank
Parachute and Nihar	Coconut Oil (India)	62	1
Hair Oil (Hair & Care, Parachute Jasmine, Parachute Advansed, Nihar Naturals, Nihar Shanti Amla, Parachute Advansed Ayurvedic hair oil, Parachute Advansed Cooling oil)	Hair Oils (India)	36	1
Saffola	Super Premium refined Edible Oils	77	1
VAHO (Parachute Beliphool, Parachute Advansed Cooling Oil, Nihar Naturals)	Value added Hair oil (Bangladesh)	23	2
Saffola Oats *	Oats (India)	34	2
Livon and Silk & Shine	Post wash Leave– On Serums	65	1
Setwet and Parachute after shower*	Hair Creams/Gels (India)	59	1
Parachute (Bangladesh)	Coconut Oil (Bangladesh)	82	1
X-Men*	Men's shampoo (Vietnam)	37	1

Source: DART, Company (* Value market share)

Exhibit 4: Various brands performance

Key businesses	Q1FY19	Q2FY19	Q3FY19	Q4FY19	Q1FY20	Q2FY20	Q3FY20	Q4FY20	Q1FY21
(Vol growth)									
Parachute Coconut Oil	9	8	9	6	9	(1)	(2)	(8)	(11)
Value Added Hair Oil (VAHO)	15	5	7	1	7	0	(7)	(11)	(30)
Saffola	10	5	2	18	3	1	11	25	16

Source: DART, Company

Exhibit 5: Summary of growth: Reported value growth (%)

Category / Business	Q1FY19	Q2FY19	Q3FY19	Q4FY19	Q1FY20	Q2FY20	Q3FY20	Q4FY20	Q1FY21	Indicative share to Group's Turnover basis FY20 results
Group	20	20	15	9	7	0	(2)	(7)	(11)	100
India business (incl youth brands)	23	20	13	7	6	(3)	(5)	(8)	(15)	77
Parachute Coconut Oil (rigid packs)	38	32	19	4	8	(4)	(5)	(12)	(12)	38
Value added hair oil	12	12	19	7	11	(6)	(17)	(18)	(32)	24
Saffola (refined edible oil)	9	9	8	15	6	5	13	25	16	20
International business	9	18	21	14	9	8	8	(5)	2	23

Source: DART, Company

Exhibit 6: YoY growth across international business in CC (%)

Region	Q1FY19	Q2FY19	Q3FY19	Q4FY19	Q1FY20	Q2FY20	Q3FY20	Q4FY20	Q1FY21	% of overseas business (in FY20)
Bangladesh	9	10	16	12	11	15	15	6	10	49
MENA	17	19	8	5	2	(3)	(4)	(50)	(27)	12
South Africa	7	18	0	0	6	(2)	3	(26)	(25)	7
South East Asia	0	14	13	4	8	1	3	5	(17)	26

Source: DART, Company





Concall highlights


- During Q1FY21, general trade sales in urban and rural declined by 17% and 10% in volume terms, respectively. Modern Trade de-grew by 17% in Q1 and is likely to pick up gradually with no further lockdowns.
- E-Commerce grew by 37%. CSD declined by 48%, due to scaled down operations during Q1FY21. E- com contributed 7% in Q1FY21 compared to 5% last year.
- More than 90% of the portfolio gained market share on a MAT June'20 basis. Except discretionary, Marico's portfolio is growing well.
- Copra prices increased 7% in Q1FY21. Company expects mildly bearish trends in copra prices for rest of the year. Rice bran oil was up 17% YoY, while LLP and HDPE prices were down by 9% and 14% YoY respectively.
- Marico will focus on SKU rationalization especially in discretionary portfolio going ahead to bring about incremental efficiencies in its supply chain operations. Some SKU's will be permanently discontinued. It is currently working with 70-80% of SKU's.
- Marico reaches 5.1 mn retail outlets by its nationwide distribution network, of which 0.9-1 mn outlets are serviced directly. Company was able to service only 70-75% outlets regularly.
- Company could resume meaningful billing of VAHO in last week of April'20 and witnessed healthy traction, especially in the bottom of the pyramid segment. Marico recorded no sale in premium personal care In the month.
- Company saw recovery in May and June, with overall India volume growth of 3% YoY in the 2 months.
- Company has taken a 5-6% cut in pricing (net) in Parachute through promotional pricing. We believe this will help the category gain market share.
- Company is working at low distributor inventory levels to ensure ROI of channel partners is optimized. It will go for restocking after the situation improves.
- Potential 20% Saffola growth was stunted due to CSD and MT channels.
- There was a shift in spends from non-media to media channels, a trend that will continue in the near term. Core portfolio spends in May and June were at 90%, A&SP cuts were in discretionary part of the portfolio. Company expects 100-150bps reduction in A&SP spends in rest of FY21 compared to 10% in FY20.
- The Foods franchise posted value growth of 30% in Q1FY21, led by 41% growth in the Saffola Oats franchise. The company expanded the Foods portfolio with the launch of Saffola Honey.
- Company expects operating margins ~20%+ for 9MFY21 with rationalization in A&SP spends.
- As per the management, hygiene portfolio is likely to reach Rs 0.8-1.0bn in FY21E. Food business is likely to clock Rs 3-3.5bn in FY21E and Rs 5bn by FY22E.
- Company expects Q2FY21 to be more volatile than Q1 due to localized lockdowns.






- In the hair oil category, organized players are likely to benefit going ahead due to better supply chain, distribution and trust factor for branded products.
- For Parachute, Rural market share (MS) is 46% while urban MS stands at 60%.
- Mediker Hand Sanitizers and Veggie Clean are available across all channels and received encouraging response due to Covid threat. Sanitizers have contributed 1.5% to entire portfolio. Surface disinfectants- House Protect and Travel Protect are currently restricted to E-com and MT.
- The capex is estimated to be ~` 1.25-1.5bn in FY21E.

Exhibit 7: Price trend of HDPE Rs / kg




Source: DART, Company



Source: DART, Company

Exhibit 8: Price trend of copra Rs /100kg



Source: DART, Company




Exhibit 10: Other key raw materials price trend Rs/10kg

Source: DART, Company





Profit	and	Loss	Account	
--------	-----	------	---------	--

(Rs Mn)	FY19A	FY20A	FY21E	FY22E
Revenue	73,340	73,150	73,596	79,419
Total Expense	60,080	58,460	58,949	64,115
COGS	40,170	37,450	38,289	41,434
Employees Cost	4,660	4,780	4,951	5,212
Other expenses	15,250	16,230	15,709	17,469
EBIDTA	13,260	14,690	14,646	15,304
Depreciation	1,310	1,400	1,611	1,693
EBIT	11,950	13,290	13,036	13,611
Interest	400	500	564	588
Other Income	1,030	1,241	1,805	2,224
Exc. / E.O. items	1,880	(290)	0	0
EBT	14,460	13,741	14,277	15,247
Tax	3,140	3,310	3,050	3,230
RPAT	11,140	10,211	11,028	11,809
Minority Interest	180	220	198	208
Profit/Loss share of associates	0	0	0	0
АРАТ	9,260	10,501	11,028	11,809

Balance Sheet				
(Rs Mn)	FY19A	FY20A	FY21E	FY22E
Sources of Funds				
Equity Capital	1,291	1,291	1,291	1,291
Minority Interest	110	130	328	537
Reserves & Surplus	28,692	28,940	32,514	36,546
Net Worth	29,983	30,230	33,804	37,836
Total Debt	3,520	3,350	3,520	3,520
Net Deferred Tax Liability	(1,760)	(1,530)	(72)	(78)
Total Capital Employed	31,853	32,180	37,581	41,816

Net Block	11,476	13,760	13,899	14,207
CWIP	450	580	450	450
Investments	590	1,050	590	590
Current Assets, Loans & Advances	33,030	33,410	34,305	39,183
Inventories	14,110	13,800	14,844	16,028
Receivables	5,170	5,390	4,781	4,932
Cash and Bank Balances	5,520	2,790	6,882	10,253
Loans and Advances	4,320	5,150	3,888	4,060
Other Current Assets	0	0	0	0
Less: Current Liabilities & Provisions	13,693	16,619	11,664	12,614
Payables	9,470	9,780	9,840	10,618
Other Current Liabilities	4,223	6,839	1,824	1,996
sub total				
Net Current Assets	19,337	16,791	22,641	26,569
Total Assets	31,853	32,180	37,581	41,816





Particulars	FY19A	FY20A	FY21E	FY22E
(A) Margins (%)				
Gross Profit Margin	45.2	48.8	48.0	47.8
EBIDTA Margin	18.1	20.1	19.9	19.3
EBIT Margin	16.3	18.2	17.7	17.1
Tax rate	21.7	24.1	21.4	21.2
Net Profit Margin	15.2	14.0	15.0	14.9
(B) As Percentage of Net Sales (%)				
COGS	54.8	51.2	52.0	52.2
Employee	6.4	6.5	6.7	6.6
Other	20.8	22.2	21.3	22.0
(C) Measure of Financial Status				
Gross Debt / Equity	0.1	0.1	0.1	0.1
Interest Coverage	29.9	26.6	23.1	23.2
Inventory days	70	69	74	74
Debtors days	26	27	24	23
Average Cost of Debt	12.0	14.6	16.4	16.7
Payable days	47	49	49	49
Working Capital days	96	84	112	122
FA T/O	6.4	5.3	5.3	5.6
(D) Measures of Investment				
AEPS (Rs)	7.2	8.1	8.5	9.1
CEPS (Rs)	8.2	9.2	9.8	10.5
DPS (Rs)	5.3	7.9	5.8	6.0
Dividend Payout (%)	73.7	97.6	67.6	65.9
BVPS (Rs)	23.2	23.4	26.2	29.3
RoANW (%)	40.2	33.9	34.4	33.0
RoACE (%)	32.4	35.0	33.8	31.8
RoAIC (%)	44.9	47.7	43.4	43.7
(E) Valuation Ratios				
CMP (Rs)	350	350	350	350
P/E	48.9	43.1	41.0	38.3
Mcap (Rs Mn)	452,361	452,361	452,361	452,361
MCap/ Sales	6.2	6.2	6.1	5.7
EV	446,451	446,641	445,089	441,718
EV/Sales	6.1	6.1	6.0	5.6
ev/ebitda	33.7	30.4	30.4	28.9
P/BV	15.1	15.0	13.4	12.0
Dividend Yield (%)	1.5	2.3	1.6	1.7
(F) Growth Rate (%)				
Revenue	16.0	(0.3)	0.6	7.9
EBITDA	16.7	10.8	(0.3)	4.5
EBIT	14.1	11.2	(1.9)	4.4
PBT	29.5	(5.0)	3.9	6.8
APAT	13.8	13.4	5.0	7.1
EPS	13.8	13.4	5.0	7.1

cash non				
(Rs Mn)	FY19A	FY20A	FY21E	FY22E
CFO	10,968	14,834	10,730	13,736
CFI	(630)	(6,644)	1,210	(2,000)
CFF	(6,820)	(10,920)	(7,848)	(8,364)
FCFF	9,368	11,020	9,110	11,736
Opening Cash	2,002	5,520	2,790	6,882
Closing Cash	5,520	2,790	6,882	10,253
E – Estimates				





DART RATING MATRIX

Total Return Expectation (12 Months)
----------------------------	------------

Buy	> 20%
Accumulate	10 to 20%
Reduce	0 to 10%
Sell	< 0%

Rating and Target Price History



Month	Rating	TP (Rs.)	Price (Rs.)
Jul-19	Accumulate	388	365
Aug-19	Accumulate	388	363
Jan-20	Accumulate	345	315
Mar-20	Accumulate	284	256
Mar-20	Reduce	284	267
May-20	Accumulate	320	284

*Price as on recommendation date

DART Team

Purvag Shah	Managing Director	purvag@dolatcapital.com	+9122 4096 9747	
Amit Khurana, CFA	Head of Equities	amit@dolatcapital.com	+9122 4096 9745	
CONTACT DETAILS				
Equity Sales	Designation	E-mail	Direct Lines	
Dinesh Bajaj	VP - Equity Sales	dineshb@dolatcapital.com	+9122 4096 9709	
Kartik Sadagopan	VP - Equity Sales	kartiks@dolatcapital.com	+9122 4096 9762	
Kapil Yadav	VP - Equity Sales	kapil@dolatcapital.com	+9122 4096 9735	
Ashwani Kandoi	AVP – Equity Sales	ashwanik@dolatcapital.com	+9122 4096 9725	
Lekha Nahar	Manager – Equity Sales	lekhan@dolatcapital.com	+9122 4096 9740	
Equity Trading	Designation	E-mail		
P. Sridhar	SVP and Head of Sales Trading	sridhar@dolatcapital.com	+9122 4096 9728	
Chandrakant Ware	VP - Sales Trading	chandrakant@dolatcapital.con	n +9122 4096 9707	
Shirish Thakkar	VP - Head Domestic Derivatives Sales Trading	shirisht@dolatcapital.com	+9122 4096 9702	
Kartik Mehta	Asia Head Derivatives	kartikm@dolatcapital.com	+9122 4096 9715	
Bhavin Mehta	VP - Derivatives Strategist	bhavinm@dolatcapital.com	+9122 4096 9705	



Analyst(s) Certification

The research analyst(s), with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

I. Analyst(s) and Associate (S) holding in the Stock(s): (Nil)

II. Disclaimer:

This research report has been prepared by Dolat Capital Market Private Limited. to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies) solely for the purpose of information of the select recipient of this report. This report and/or any part thereof, may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of Dolat Capital Market Private Limited. This report has been prepared independent of the companies covered herein. Dolat Capital Market Private Limited. and its affiliated companies are part of a multi-service, integrated investment banking, brokerage and financing group. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have provided or may provide services in respect of managing offerings of securities, corporate finance, investment banking, mergers & acquisitions, financing or any other advisory services to the company(ies) covered herein. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have received or may receive compensation from the company(ies) mentioned in this report for rendering any of the above services. Research analysts and sales persons of Dolat Capital Market Private Limited. may provide important inputs to its affiliated company(ies) associated with it. While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and Dolat Capital Market Private Limited. does not warrant its accuracy or completeness. Dolat Capital Market Private Limited. may not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This report is provided for information only and is not an investment advice and must not alone be taken as the basis for an investment decision. The investment discussed or views expressed herein may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The information contained herein may be changed without notice and Dolat Capital Market Private Limited. reserves the right to make modifications and alterations to this statement as they may deem fit from time to time. Dolat Capital Market Private Limited. and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. This report is neither an offer nor solicitation of an offer to buy and/or sell any securities mentioned herein and/or not an official confirmation of any transaction. This report is not directed or intended for distribution to, or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Dolat Capital Market Private Limited. and/or its affiliated company(ies) to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this report may come, are required to inform themselves of and to observe such restrictions.

For U.S. Entity/ persons only: This research report is a product of Dolat Capital Market Private Limited., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Dolat Capital Market Private Limited. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person or entity.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Dolat Capital Market Private Limited. has entered into an agreement with a U.S. registered brokerdealer Ltd Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer/Entity as informed by Dolat Capital Market Private Limited. from time to time.

Dolat Capital Market Private Limited.

Corporate Identity Number: U65990DD1993PTC009797 Member: BSE Limited and National Stock Exchange of India Limited. SEBI Registration No: BSE - INB010710052 & INF010710052, NSE - INB230710031& INF230710031, Research: INH000000685 Registered office: Office No. 141, Centre Point, Somnath, Daman – 396 210, Daman & Diu Board: +9122 40969700 | Fax: +9122 22651278 | Email: research@dolatcapital.com | www.dolatresearch.com